...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol.
【24h】

Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol.

机译:在抗alphabeta T细胞受体单克隆抗体和环孢菌素A方案下,完全主要组织相容性与主要组织相容性复杂的肢体同种异体移植物中的供体特异性耐受。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Recent studies have demonstrated that treatment with alphabeta-T-cell receptor (TCR) monoclonal antibody and cyclosporine A (CsA) can extend survival in composite tissue allografts (CTA). The purpose of this study was to induce tolerance in fully major histocompatibility complex (MHC)-mismatched rat limb allografts under 7 days of a combined alphabeta-TCR-CsA protocol. METHODS: The authors performed 30 hind-limb allotransplantations across the MHC barrier between Brown Norway donors (BN; RT1n) and Lewis recipients (LEW; RT1l). Isograft and allograft controls received no treatment. The experimental groups received monotherapy of alphabeta-TCR and CsA or a combination of alphabeta-TCR and CsA for 7 days only. Donor-specific tolerance and immunocompetence were determined by standard skin grafting in vivo and mixed lymphocyte reaction (MLR) in vitro. The efficacy of immunosuppressive therapy and the level of donor-specific chimerism were determined by flow cytometry. RESULTS: Long-term survival(>350 days) was achieved in allograft recipients (n=6) under the 7-day protocol of combined alphabeta-TCR-CsA. Donor-specific tolerance and immunocompetence of long-term chimeras were confirmed by acceptance of skin grafts from the donors and rejection of the third-party alloantigens (AxC Irish). At day 120, MLR demonstrated unresponsiveness to the host and donor antigens but strong reactivity against third-party alloantigens. Flow cytometry confirmed the high efficacy of immunosuppressive treatment and the development of donor-specific chimerism (7.6% of CD4+-RT1n+ cells, 1.3% of CD8+-RT1n+ cells, and 16.5% of CD45RA+-RT1n+ cells) in the periphery of tolerated recipients. CONCLUSIONS: Combined therapy of alphabeta-TCR-CsA for 7 days resulted in tolerance induction in fully MHC-mismatched rat hind-limb allografts. Tolerance was directly associated with stable, donor-specific chimerism.
机译:背景:最近的研究表明,用字母T细胞受体(TCR)单克隆抗体和环孢菌素A(CsA)进行治疗可以延长复合组织同种异体移植(CTA)的生存期。这项研究的目的是在7天内联合字母-TCR-CsA方案诱导完全主要的组织相容性复合体(MHC)不匹配的大鼠肢体同种异体移植耐受。方法:作者在布朗挪威捐赠者(BN; RT1n)和刘易斯接受者(LEW; RT11)之间的MHC屏障上进行了30次后肢同种异体移植。同种异体移植和同种异体移植对照均未接受治疗。实验组仅接受了7天的Alphabeta-TCR和CsA单一疗法或Alphabeta-TCR和CsA的联合疗法。供体特异性耐受性和免疫能力通过体内标准皮肤移植和体外混合淋巴细胞反应(MLR)确定。通过流式细胞术确定免疫抑制疗法的疗效和供体特异性嵌合水平。结果:在7天的alphabeta-TCR-CsA联合治疗方案下,同种异体移植受者(n = 6)获得了长期存活(> 350天)。通过接受来自供体的皮肤移植物并拒绝第三方同种异体抗原(AxC Irish),证实了长期嵌合体的供体特异性耐受和免疫能力。在第120天,MLR对宿主和供体抗原无反应,但对第三方同种异体抗原的反应性强。流式细胞仪证实了免疫抑制治疗的高效率和供体特异性嵌合体的发展(7.6%的CD4 + -RT1n +细胞,1.3%的CD8 + -RT1n +细胞和16.5%的CD45RA + -RT1n +细胞)在耐受的受者周围。结论:7天的alphabeta-TCR-CsA联合治疗导致完全MHC不匹配的大鼠后肢同种异体移植耐受诱导。宽容与稳定的,特定于供体的嵌合直接相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号